| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
The INSPIRE Trial Prospectively Assesses Pulse Oximeter Accuracy Using a Unique Real-world Study Design and in the Feasibility ...
Masimo (NASDAQ: MASI) has outperformed the market over the past 10 years by 1.12% on an annualized basis producing an average a...
BTIG analyst Marie Thibault reiterates Masimo (NASDAQ:MASI) with a Buy and maintains $198 price target.
Powell's dovish Jackson Hole tone, mixed WMT/TGT/TJX earnings, and an AI hangover led by PLTR's slide gave way to a lat...
Apple reintroduced blood-oxygen tracking on its watches after a Customs ruling, but Masimo has sued to block the feature again.
Now Available for Both Cerebral and Somatic Applications and for All Patient Populations, O3's Delta Hemoglobin Parameters ...